Pyridinium and quinolinium derivatives
The invention provides compounds of formula I which block phosphorylcholine biosynthesis by selectively blocking the enzyme choline kinase in tumour cells or in cells affected by parasitic infection and which, consequently, find application in the treatment of tumours and parasitic or virus and fungal diseases in animals, including humans; as well as a method for the preparation of the compounds of the invention, and certain intermediates of said method.
Inventor/s: : Juan Carlos Lacal Sanjuán; Joaquín Campos Rosa; Miguel Angel Gallo Mezo; Antonio Espinosa Ubeda
Application No.: US20110178124
ENTITY OWNING THE RIGHTS: CSIC, University of Granada
APPLICATION NUMBER: US20110178124
COUNTRY OF REGISTRATION: United States of America
DATE OF REGISTRATION: 13/08/2010
GRANT DATE: 19/11/2013
TYPE OF INDUSTRIAL PROPERTY: Patent of invention.
Countries to which it has spread: Brazil, Canada, India, Japan, South Korea, China (Sun No: 200580002428.9); Europe (Sun No: EP05708100.2); Mexico (Sun No: PA/a/2006/007940); United States (Sun No: 10/597.095) and Hong Kong (Sun No: 07108357.3).
Advantages
On 6 May 2004, a licence agreement was signed with the company Oncopharma S.L. to exploit this patent, which was terminated on 6 April 2006. On 6 April 2006, a licence agreement was signed with the company Translational Drug Pharma (TCDPharma), located at the Centro Nacional de Biotecnología, c/Darwin 3, Campus de Cantoblanco, 08049 Madrid, which is currently in force. The company is a platform based on the knowledge of the activity, inhibitors and metabolic activity of the Choline Kinase enzyme and its role in different types of tumours present in highly prevalent cancers: lung, breast, bladder, colorectal and pancreatic.
RSS
